Lorlatinib After Five Years: TP53 and EML4::ALK Variant 3 Refine Prognosis but Do Not Defi
Audio narration · Coming soon
Five-year data on lorlatinib treatment for ALK-positive NSCLC reveal that TP53 mutations predict poorer survival, while EML4::ALK variants and circulating tumor DNA help clarify resistance mechanisms. These factors refine prognosis but do not determine treatment benefit.
Why this matters
PRISM scored this story 65/100 for interest.
Originally published by gnews